Valuation air-pocket: still 35× forward on ~10% growth, so any organic-growth or margin miss re-rates the stock lower
One-line thesis. Rollins is one of the highest-quality recurring-revenue compounders in the S&P 500 — Orkin pest control, 2.8M customers, 37% ROE, light debt, ~90% U.S. — but even after a 34% drawdown it trades at ~35× forward earnings for ~10% EPS growth, so the price still has to catch down to the (excellent) business rather than the reverse. Watch; buy quality when the multiple is sane.
◆ Synthos call — HoldROL is a solid business largely reflected at ~$41 — fine to keep, no reason to chase; it gets interesting again below ~$35.
Downside Risk (lower = safer)
5/10 · Moderate
Low beta (0.73), light leverage (1.1x net debt/EBITDA), recession-resistant recurring revenue — but 35x forward EPS on ~10% growth (PEG ~3.3) mid a sharp de-rating.
~10% growth and decelerating (organic slowed to 6.6% in Q1'26); mature slow-TAM pest market caps the multibagger even with roll-up optionality.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 23%/yrTo justify today’s $43, earnings would have to compound roughly 23% a year for 10 years (9% discount rate). Analysts forecast ~9%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Rollins is the company behind Orkin and a family of pest-control brands — the folks who come spray your house or your restaurant for bugs, rodents, and termites. It's a boringly good business: customers pay every month or every quarter, year after year, so the revenue is sticky and recession-resistant. Bugs don't take a holiday.
The problem is price, not quality. The stock got very popular and very expensive, and it has fallen about a third from its high — but it still costs about 35 dollars for every 1 dollar of expected earnings, while those earnings are only growing about 10% a year. That's a lot to pay for steady-but-slow growth. Our verdict is Watch: a wonderful company we'd happily own at a fairer price, but not a screaming buy today.
Here's what our three scores mean in everyday terms:
Downside Risk 5/10 (middle). The company itself is very safe — low debt, calm stock, dependable customers — but the price is high, so a disappointment can still hurt.
Growth Quality 7/10 (good). A high-quality, dependable grower. Not explosive, but clean and durable.
Exponential Potential 3/10 (low). Don't expect it to double fast. It grows a steady ~10% a year in a mature, slow-moving industry.
The one big worry: you're paying a premium price for modest growth, and that growth just slowed (organic sales grew only ~6.6% early this year). If growth or profit margins slip again, the expensive stock can keep sliding.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLY (sector)), set to 100 a year ago
Solid = ROL · dashed = S&P 500 · dotted = XLY (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$43.38
Market cap$21B
P/E trailing2×
P/E FY26E / FY27E35× / 31×
EV / Sales5.7×
EV / EBITDA25.4×
Gross margin51.8%
Net margin13.8%
Dividend yield1.64%
Beta0.727
52-wk range$42 – $66
RSI(14)29
50 / 200-DMA$50 / $56
12-mo return+-23% (SPY +21%)
Street target$60 ($46–$70)
Analyst grades8 Buy · 10 Hold · 0 Sell
FMP ratingB+
Next earnings2026-08-05
What the experts actually said 0 traceable claims on ROL · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Rollins, Inc. (NYSE: ROL) is a ~$21B global pest and wildlife management company headquartered in Atlanta, founded 1948. Through Orkin and a family of brands (HomeTeam, Clark, Fox, Western, Northwest, Trutech/Critter Control, Orkin Canada/Australia, and more), it serves more than 2.8 million residential and commercial customers across North America, South America, Europe, Asia, Africa and Australia, with ~22,000 employees across 850+ locations. The model is recurring-service: routine pest control, termite protection, and wildlife removal on repeat contracts. Fiscal year ends December 31.
Revenue mix (FY2025, from filings):
By service line: Residential contract $1,693M (45%) · Commercial contract $1,245M (33%) · Termite/ancillary + other ~$807M (21%) · Franchise $16M. (FMP re-bucketed termite into "other" in FY25; the residential/commercial split is the durable frame.)
By geography: United States $3,491M (~93%) · Non-US $270M (~7%). The base is overwhelmingly domestic — a stability strength and a limited-international-runway limitation.
The business grows two ways: (1) organic — price plus new customers plus cross-sell — and (2) a steady tuck-in M&A roll-up of small local pest operators (e.g., the Saela and April 2026 Romex deals). Growth has been reliably high-single to low-double digit for years.
2. The expert thesis
There is no expert coverage of Rollins in the Synthos knowledge base — total_claims is 0, breadth 0, net conviction 0. No net-bullish or cautionary voices we track have made a traceable, dated claim on this name. That is an honest gap, not a hidden signal.
What that means for this note: the verdict is entirely fundamentals- and quant-driven. There are no claim_ids to cite because none exist in the file, and House Standard forbids inventing them. Everything below is built from the FMP financials, the analyst-estimate consensus, management's own SEC 8-K guidance (half-weighted, §9), and Synthos's own scoring — not from expert conviction. Read the conviction rating as Low for exactly this reason: a business this well-understood by the market simply has no differentiated expert edge in our panel.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
5 · Moderate
Beta 0.73, net-debt/EBITDA 1.1×, recession-resistant recurring revenue and a fortress operating model make the business very safe — but 35× FY26E on ~10% EPS growth (PEG ~3.3) is a rich price mid-de-rating, and the stock is already −34% from its high.
Growth Quality
7 · High
~10% forward EPS CAGR, 37% ROE, 21% ROIC, ~52% gross margin, sticky recurring revenue and a real roll-up moat — clean, durable compounding, just not fast, with margins slightly pressured (Q1'26 operating margin −120 bps YoY).
Exponential Potential
3 · Low
~10% growth that is decelerating (Q1'26 organic +6.6%), a mature slow-TAM pest market, and a $21B cap. Tuck-in M&A gives modest optionality but there is no exponential here.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Peak-season demand reaccelerates, organic growth back toward 8%+, margins re-expand, M&A stays accretive. FY27E EPS beats to ~$1.45 (vs $1.38 cons); market re-pays a premium ~36× for the quality.
~$52 (+20%)
Base(our anchor)
Estimates roughly hit — FY27E EPS $1.38; a durable ~10% compounder with recurring revenue earns a still-rich but saner ~30×.
~$41 (−6%)
Bear
Organic growth keeps slowing, cost/insurance pressure compresses margins, and the market finishes de-rating a former darling. FY27E EPS ~$1.30; multiple compresses to ~22× (still a premium to the market).
~$29 (−33%)
Synthos fair value = the base case, ~$41 (−6%), with the full $29–$52 span as the honest range. Note our anchor sits well below the Street's $60 consensus: the sell-side is still valuing ROL near its historical premium multiple, whereas we think ~10% growth no longer supports 40×+. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). ROL is a high-quality compounder with essentially no exponential profile:
Acceleration (2nd derivative) is negative. Revenue grew +11.0% (FY25) but management reported organic growth of only +6.6% in Q1'26 (10.2% total including M&A), and EPS growth flattens across the estimate strip (FY26E +13% → FY27E +12% → FY28E +10% → FY29E +11% → FY30E +4%). The trajectory is decelerating, not accelerating.
Room to run: the U.S. pest-control market is large and fragmented, which supports the roll-up — but it is a mature, low-growth end market, and at 93% U.S. revenue the international runway is under-developed. A $21B cap in a slow-TAM category does not offer a fast multibagger.
Reinvestment runway: capex is tiny (~$28M/yr, <1% of revenue — an asset-light service model), so growth reinvestment happens through M&A (~$310M FY25). Accretive, but incremental.
Exponential Potential: Low (3/10). Own ROL for dependable ~10% compounding and downside stability, not for a fast multibagger. A small, accelerating name with these returns on capital would score far higher; a mature, decelerating one does not.
Revenue: FY25 $3.76B, +11.0% (FY24 $3.39B, +10.3% on FY23 $3.07B). Steady low-double-digit top line, roughly two-thirds organic / one-third M&A.
Quarterly trajectory: Q1'25 $823M → Q2 $1,000M → Q3 $1,026M → Q4 $913M → Q1'26 $906M (+10.2% YoY). Seasonal (peak season is Q2–Q3); the YoY comparison is the signal, and organic decelerated to +6.6% in Q1'26.
Margins: gross 51.8% TTM, EBITDA 22.4% TTM, operating ~19.0%, net 13.8% TTM. Q1'26 operating margin slipped −120 bps YoY on insurance/claims and people-cost deleverage early in the quarter — a watch item, though management expects seasonal recovery.
Earnings: net income $527M FY25 (+13% on FY24 $466M); EPS $1.09 vs $0.96. Q1'26 net income $108M, EPS $0.22 (flat YoY on GAAP; adjusted EPS +9% to $0.24).
Cash flow: operating CF $678M, capex just −$28M, FCF $650M FY25 (+12%). Very high cash conversion (FCF ≈ 96% of operating CF) — the hallmark of the asset-light model. Q1'26 FCF fell 21% YoY, but management attributed it to timing of tax payments (~$40M) and a shift to semi-annual interest on the 2035 notes (~$9M), not a demand problem.
Balance sheet: total debt ~$1.04B, net debt ~$938M, net-debt/EBITDA ~1.1× — comfortably investment-grade. Returns on capital are elite: ROE 37%, ROIC 21%, ROCE 31%. (Note current ratio 0.65 and negative tangible book — normal for a goodwill-heavy roll-up, not a red flag given the cash generation.)
6. Valuation — priced in or room?
This is the crux. ROL is unambiguously expensive even after a 34% drawdown: 40× trailing EPS, 5.7× sales, 25× EV/EBITDA, price/book 15×, and a forward PEG of ~3.3. The forward P/E strip is 35× (FY26E) → 31× (FY27E) → 25× (FY30E) — the multiple only compresses to a still-premium 25× five years out if estimates hit. FMP's own letter rating flags it: overall B+, but the price-to-earnings sub-score is 1/5 and price-to-book 1/5.
The bull's defense is legitimate — a recurring-revenue, low-beta, 37%-ROE compounder deserves a premium, and ROL has spent most of the last decade at 40×+. The bear's rebuttal is that ~10% EPS growth cannot indefinitely support 40× once growth decelerates, and that's exactly what the −34% de-rating is: the market repricing a former darling toward a saner multiple. A reverse read: at $43.38 the market is paying ~30× normalized forward earnings — reasonable for the quality, but not cheap, and with little margin for a growth or margin miss.
Street targets (context): consensus $60, high $70, low $46 — the sell-side still anchors near the historical premium. Our base FV of ~$41 is deliberately below consensus because we think the multiple has further to normalize toward the growth rate. Not a value buy; a wonderful-business-at-a-still-full-price hold.
7. Technicals (from the tech block)
Trend:down. $43.38 sits below the 50-DMA ($49.82) and 200-DMA ($56.33), and the 50 is below the 200 — a death-cross posture. MACD −2.06 (negative).
Location:−33.9% off the 52-week high ($65.60), only +3.9% off the 52-week low ($41.74) — near the bottom of its range, deep in a drawdown (max −34% from peak).
Momentum: RSI(14) 28.7 — oversold (<30). A bounce is possible on mean reversion, but oversold in a downtrend is a falling-knife signal, not a green light.
Relative strength (the tell): ROL −23.4% 12-mo vs SPY +20.6% and QQQ +30.3%; −18.9% 3-mo vs SPY +13.7%. Persistent, broad underperformance — the market is actively de-rating this name.
Read: technicals do not confirm a buy. Oversold RSI may set up a tactical bounce, but the primary trend is down and the stock is underperforming both the market and the Nasdaq badly. No technical urgency to step in; a base above the 50-DMA would be the confirmation to watch for.
8. Moat & competitive position
Rollins's moat is a genuine one for a services business: (1) density and route economics — the more customers per zip code, the lower the cost-to-serve, a real local-scale advantage; (2) brand trust — Orkin is a household name in a category where people don't shop hard on price; (3) recurring contracts with high retention and pricing power (pest control is non-discretionary and a small line item for customers); and (4) a repeatable M&A roll-up engine consolidating thousands of mom-and-pop operators. Returns on capital (37% ROE, 21% ROIC) confirm the moat is real.
Peer set (from FMP — note the tags are loose): FMP's "peers" list is a grab-bag of consumer-cyclical names by market cap (Expedia $31B, Lennar $22B, PulteGroup $25B, Ulta $20B, Williams-Sonoma $27B, Tractor Supply $17B, Stellantis, Geely, Viking) — none are true pest-control comps. The real competitive frame is the pest-control oligopoly: Rentokil (RTO) — the global #1 after buying Terminix — and Terminix/private regional operators. ROL is the highest-return, cleanest-balance-sheet operator in that true peer set, which is precisely why it has carried a premium multiple.
9. Management, capital allocation & guidance
Capital allocation: disciplined and shareholder-friendly — a ~1.6% dividend (payout ~63% of earnings, FY25 dividends $328M), opportunistic buyback ($217M FY25), and steady tuck-in M&A ($310M FY25) funded by compounding FCF on a light balance sheet. Appropriate for a high-ROIC roll-up.
Insider activity: the sampled Form 4s are routine — director equity awards (April 2026), an accounting-officer award/tax-withholding, and two gifts by the CEO (Gahlhoff) and Executive Chairman (Wilson) in late April. No cluster of alarming open-market discretionary selling; nothing that changes the thesis.
Management's own guidance (half-weighted — their self-interested words): Rollins does not issue precise numeric revenue/EPS guidance, but the Q1'26 earnings release (SEC 8-K, filed 2026-04-22) is a real earnings release with forward commentary. Management framed the quarter as a "strong acceleration of demand during March," noting they "exited the quarter with approximately 12 percent total growth and over 8 percent organic growth in March," and said they "anticipate improving profitability in our underlying operations as we enter peak season," while attributing soft Q1 cash flow to tax-payment timing (~$40M) and a semi-annual interest shift (~$9M) rather than demand. CFO Krause pointed to a "balanced capital allocation program enabled by compounding cash flow and a strong balance sheet."Weight this at half — it is management talking its own book — but the March exit-rate and peak-season margin-recovery framing are the specific claims to verify against the Q2 print.
10. Catalysts & what to watch
Next earnings: 2026-07-22 (Q2'26; Street EPS $0.34, revenue ~$1.09B). Q2 is peak season — the single most important read on whether the March re-acceleration held.
Organic growth rate: did organic re-accelerate from Q1's +6.6% toward the +8% March exit-rate management flagged? This is the key valuation driver.
Operating margin: did the −120 bps Q1 margin pressure (insurance/claims, people-cost deleverage) reverse into peak season as management guided?
M&A cadence: integration and accretion of Saela, Romex (April 2026) and future tuck-ins.
Multiple normalization: whether the de-rating stabilizes — a base forming above the 50-DMA (~$50) would be the technical tell that the reset is complete.
Thesis tripwires (what would change the call): organic growth falling below mid-single digits; a second consecutive quarter of YoY margin compression; FCF conversion deteriorating structurally (not just timing); or — on the upside — the stock building a base with organic growth reaccelerating, which would move this from Watch toward Buy.
11. Key risks
Valuation / de-rating (the main risk): 35× forward on ~10% growth (PEG ~3.3) leaves no margin for error; the −34% drawdown may not be finished if growth stays soft.
Decelerating organic growth: Q1'26 organic +6.6% is below the historical run-rate; if the mature end market keeps slowing, the premium multiple is unsupportable.
Margin pressure: insurance/claims and labor costs squeezed Q1'26 operating margin −120 bps YoY — a cost-inflation risk in a labor-intensive service model.
M&A dependence: roughly a third of growth is acquired; a slower deal pipeline or overpaying would hit both growth and returns; goodwill/intangibles are 62% of assets.
Concentration / limited international runway: 93% U.S. revenue is stable but caps the geographic growth optionality.
No expert edge: with 0 KB claims, there is no differentiated conviction cushioning this call — it lives or dies on the fundamentals and the multiple.
12. Verdict, position sizing & monitoring
Watch. Rollins is a genuinely excellent business — recurring revenue, 37% ROE, light debt, low beta, a real density-and-brand moat, and a proven roll-up engine. The problem is arithmetic, not quality: even after a 34% drawdown it trades at ~35× forward earnings for ~10% EPS growth that just decelerated, and the technicals (below both moving averages, RSI oversold in a downtrend, −23% vs a +21% market) say the market is still repricing it. Our base-case fair value (~$41) sits below both the current price and the Street's $60 consensus — the price still needs to catch down to the business.
Sizing: if already owned, hold as a small 1–3% quality-defensive sleeve. For new money, there is no urgency — wait for either a saner multiple (high-20s forward P/E) or evidence organic growth has re-accelerated. This is a name to buy on quality when the price is right, and today it isn't quite.
Monitoring: the 2026-07-22 peak-season print is the key data point — watch organic growth and operating margin against management's March exit-rate and margin-recovery claims. Formal re-score each earnings print.
Single biggest risk: the valuation air-pocket — paying up for modest, decelerating growth means any miss re-rates the stock further.
Why not "Buy"? The business would justify it; the price does not yet. Why not "Avoid"? The quality, balance sheet, and cash generation are too good, and the de-rating has already removed much of the excess — a Watch that converts to Buy on a better entry is the honest call.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — there is no expert coverage of ROL in the Synthos knowledge base. No claim_ids are cited because none exist; fabricating conviction is structurally forbidden. The verdict is fundamentals- and quant-driven.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from SEC 8-K filed 2026-04-22. Forward figures are analyst consensus (FMP) or Synthos scenarios, labeled as estimates.
Management caveat: the §9 guidance is management's own earnings-release language, half-weighted by design.
Peer-list caveat: FMP's peer tags for ROL are consumer-cyclical-by-market-cap, not true pest-control comps; the real comp is Rentokil/Terminix (noted in §8).
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").